M
Michelle Remme
Researcher at University of London
Publications - 20
Citations - 583
Michelle Remme is an academic researcher from University of London. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Cost effectiveness. The author has an hindex of 9, co-authored 18 publications receiving 536 citations. Previous affiliations of Michelle Remme include Ifakara Health Institute & United Nations.
Papers
More filters
Journal ArticleDOI
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: A combined analysis of 12 mathematical models
Jeffrey W. Eaton,Nicolas A Menzies,John Stover,Valentina Cambiano,Leonid Chindelevitch,Anne Cori,Jan A. C. Hontelez,Jan A. C. Hontelez,Jan A. C. Hontelez,Salal Humair,Cliff C. Kerr,Daniel J. Klein,Sharmistha Mishra,Sharmistha Mishra,Kate M. Mitchell,Brooke E Nichols,Peter Vickerman,Roel Bakker,Till Bärnighausen,Till Bärnighausen,Anna Bershteyn,David E. Bloom,Marie-Claude Boily,Stewart T. Chang,Ted Cohen,Ted Cohen,Peter J. Dodd,Christophe Fraser,Chaitra Gopalappa,Jens D Lundgren,Jens D Lundgren,Natasha K. Martin,Natasha K. Martin,Evelinn Mikkelsen,Elisa Mountain,Quang D. Pham,Michael Pickles,Andrew N. Phillips,Lucy Platt,Carel Pretorius,H Prudden,Joshua A. Salomon,David A. M. C. van de Vijver,Sake J. de Vlas,Bradley G. Wagner,Richard G. White,David Wilson,Lei Zhang,John M. Blandford,Gesine Meyer-Rath,Gesine Meyer-Rath,Michelle Remme,Paul Revill,Nalinee Sangrujee,Fern Terris-Prestholt,Meg Doherty,Nathan Shaffer,Philippa Easterbrook,Gottfried Hirnschall,Timothy B. Hallett +59 more
TL;DR: Estimates suggest that earlier eligibility for antiretroviral therapy is very cost effective in low-income and middle-income settings, although these estimates should be revisited when more data become available.
Journal ArticleDOI
Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries
TL;DR: The data available on costs, efficiency and economies of scale and scope for the six basic programmes of the UNAIDS Strategic Investment Framework are synthesized to inform those planning the scale-up of human immunodeficiency virus services in low- and middle-income countries.
Journal ArticleDOI
Financing Essential HIV Services: A New Economic Agenda
Anna Vassall,Michelle Remme,Charlotte Watts,Timothy B. Hallett,Mariana Siapka,Peter Vickerman,Fern Terris-Prestholt,Markus Haacker,Lori Heise,Andy Haines,Rifat Atun,Peter Piot +11 more
TL;DR: The need for, and challenges facing, innovative and sustainable financing of the HIV response is discussed in Anna Vassall and colleagues' discussion.
Journal ArticleDOI
Financing structural interventions: going beyond HIV-only value for money assessments
TL;DR: It is found that efficient structural interventions may be less likely to be prioritized, financed and taken to scale where sectors evaluate their options in isolation and their cross-sectoral benefits foregone.
Journal ArticleDOI
The cost and cost-effectiveness of gender-responsive interventions for HIV: a systematic review.
Michelle Remme,Mariana Siapka,Anna Vassall,Lori Heise,Jantine Jacobi,Claudia Ahumada,Charlotte Watts +6 more
TL;DR: This work assesses current evidence on what forms of gender‐responsive intervention may enhance the effectiveness of basic HIV programmes and be cost‐effective.